Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Insight Molecular Diagnostics (IMDX) Operating Expenses (2020 - 2025)

Insight Molecular Diagnostics (IMDX) has disclosed Operating Expenses for 6 consecutive years, with $23.9 million as the latest value for Q4 2025.

  • Quarterly Operating Expenses fell 30.07% to $23.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $53.4 million through Dec 2025, down 13.51% year-over-year, with the annual reading at $53.4 million for FY2025, 13.53% down from the prior year.
  • Operating Expenses hit $23.9 million in Q4 2025 for Insight Molecular Diagnostics, up from $11.2 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $34.2 million in Q4 2024 to a low of -$5.8 million in Q1 2023.
  • Historically, Operating Expenses has averaged $10.7 million across 5 years, with a median of $10.7 million in 2025.
  • Biggest YoY gain for Operating Expenses was 416.96% in 2023; the steepest drop was 278.92% in 2023.
  • Year by year, Operating Expenses stood at $17.8 million in 2021, then tumbled by 34.69% to $11.6 million in 2022, then skyrocketed by 38.22% to $16.1 million in 2023, then surged by 113.06% to $34.2 million in 2024, then tumbled by 30.07% to $23.9 million in 2025.
  • Business Quant data shows Operating Expenses for IMDX at $23.9 million in Q4 2025, $11.2 million in Q3 2025, and $10.2 million in Q2 2025.